sapanisertib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Sapanisertib is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2.   Wikipedia

Chemistry

  • SMILES: CC(C)n1nc(c2ccc3oc(N)nc3c2)c4c(N)ncnc14
  • InChIKey: GYLDXIAOMVERTK-UHFFFAOYSA-N
  • Mol. Mass: 309.33
  • ALogP: 2.38
  • ChEMBL Molecules:
    ink-128  
    sapanisertib  
More Chemistry

Pharmacology

Alternative names

ink128 | ink-128 | mln0128 | mln-0128 | sapanisertib | tak-228

Organizations (28)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (50)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (50)


 

Bile Duct Neoplasms (Phase 2)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Merkel Cell (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Fibrosarcoma (Phase 1/Phase 2)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Hamartoma (Phase 2)

Hematologic Neoplasms (Phase 1)

Hodgkin Disease (Phase 1)

Kidney Neoplasms (Phase 2)

Leiomyosarcoma (Phase 1/Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 1)

Lymphoma, T-Cell (Phase 1)

Melanoma (Phase 2)

Meningeal Neoplasms (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Nerve Sheath Neoplasms (Phase 1/Phase 2)

Ovarian Diseases (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Synovial (Phase 1/Phase 2)

Skin Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Thyroid Carcinoma, Anaplastic (Phase 2)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 45
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue